Key Insights

Highlights

Success Rate

50% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 87/100

Termination Rate

33.3%

9 terminated out of 27 trials

Success Rate

50.0%

-36.5% vs benchmark

Late-Stage Pipeline

4%

1 trials in Phase 3/4

Results Transparency

44%

4 of 9 completed with results

Key Signals

4 with results50% success

Data Visualizations

Phase Distribution

24Total
Not Applicable (10)
P 1 (7)
P 2 (6)
P 3 (1)

Trial Status

Completed9
Terminated9
Recruiting4
Withdrawn2
Active Not Recruiting2
Unknown1

Trial Success Rate

50.0%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (27)

Showing 20 of 20 trials
NCT06483308Not ApplicableActive Not RecruitingPrimary

Shortened High-dose Palliative Radiotherapy for Lung Cancer

NCT06383988Not ApplicableActive Not Recruiting

A Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources

NCT06538038Recruiting

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

NCT07176559Not ApplicableRecruitingPrimary

Pilot Randomized Clinical Trial of Informational Support Versus Spiritual Care

NCT06654245Not ApplicableTerminated

Assessing and Addressing Follow-up Care Needs That Will Facilitate Care Transitions for Cancer Survivors

NCT02606149Not ApplicableCompletedPrimary

Truthful Information on Chemotherapy and Its Impact on Chemotherapy at the End of Life

NCT03867175Phase 3Completed

Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer

NCT02318771Phase 1Completed

Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer

NCT06896890Phase 1Recruiting

Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer

NCT04985357Withdrawn

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

NCT06427369Phase 1Withdrawn

An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer

NCT06110572Phase 1Recruiting

Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation

NCT05435846Phase 1Terminated

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

NCT02693080Phase 1Completed

CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy

NCT05025748Not ApplicableCompleted

Ask Questions (ASQ):Implementation of a Communication Intervention

NCT04005144Phase 1Terminated

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

NCT04267575Not ApplicableUnknown

Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites

NCT03112668Not ApplicableCompleted

Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners

NCT03222258Completed

Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients

NCT01556191Phase 2CompletedPrimary

Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR

Scroll to load more

Research Network

Activity Timeline